Therapy of advanced prostate cancer with granulocyte macrophage colony- stimulating factor

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1738-1744

  Small, Eric J ^a,c   Reese, David M ^a   Um, Bonnie ^a   Whisenant, Sarah ^a   Dixon, Shannon C ^b   Figg, William D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTIGEN DETECTION; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; FATIGUE; FEVER; HUMAN; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CELL DIVISION; COHORT STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0032809320     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, T. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-30, 1998.
2. Vogelzang, N. One hundred thirteen men with prostate cancer died today. J. Clin. Oncol., 14: 1753-1755, 1996.
3. Fagerberg, J. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Med. Oncol., 13: 155-160, 1996.
4. Thomas, R., and Lipsky, P. E. Dendritic cells: origin and differentiation. Stem Cells, 14: 196-206, 1996.
5. Jaffee, E. M., Lazenby, A. J., Meurer, J., Marshall, F., Hauda, K. M., Clunts, C., Hurwitz, H., Simons, J., Levitsky, H. I., and Pardoll, D. M. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J. Immunother., 18: 1-9, 1995.
6. Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hirofumi, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
7. Viewig, J., Rosenthal, F. M., Bannerji, R., Hestin, W. D., Fair, W. R., Gansbacher, B., and Gilboa, E. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res., 54: 1760-1765, 1994.
8. Rini, I., Stadler, W. M., Spielberger, R. T., Ratain, M. J., and Voglezang, N. T. Granulocyte-macrophage colony-stimulating factor in metastatic renal cell carcinoma: a Phase II trial. Cancer (Phila.), 82: 1352-1358, 1998.
9. Wos, E., Olencki, T., Tuasan, L., Budd, G. T., Peereboom, D., Sandstrom, K., McLain, D., Finke, J., and Bukowski, R. M. Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer (Phila.), 77: 1149-1153, 1996.
10. Spitler, L. E., Grossbard, M. L., Ernstoff, M. S., Silver, G., Jacobs, M., Hayes, F. A., and Soong, S. J. Adjuvant therapy of stage III and stage IV malignant melanoma using yeast-derived GM-CSF. In: Proceedings of the 2nd International Conference on the Adjuvant Therapy of Malignant Melanoma, 1997.
11. Thalmann, G. N., Sikes, R. A., Chang, S. M., Johnston, D. A., von Eschenbach, A. C., and Chung, L. W. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J. Natl. Cancer Inst., 88: 794-801, 1996.
12. Eisenberger, M. A., and Nelson, W. G. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J. Natl. Cancer Inst., 88: 1835-1843, 1996.
13. Horoszewicz, J. S., Lying, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
14. Ishibashi, T., Yokoyana, K., Shindo, J., Hawazaki, Y., Endo, Y., Sato, T., Takahashi, S., Kawarabayasi, Y., Shiomi, M., and Yamamoto, T. Potent cholesterol-lowering effect by human granulocyte-macrophage colony stimulating factor in rabbits. Arteriocler. Thromb., 14: 1534-1541, 1994.
15. Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V., Schwartz, M., and Fossa, S. D. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566-1572, 1993.
16. Smith, D. C., Dunn, R. L., Strawderman, M. S., and Pienta, K. J. Change in serum prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 16: 1835-1843, 1998.
17. Figg, W. D., Sartor, O., Cooper, M. R., Thibault, A., Bergan, R. C., Dawson, N., Reed, E., and Myers, C. E. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am. J. Med., 98: 412-414, 1995.